AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31076620 — intervention group
Group type: EXPERIMENTAL
Intervention: CNN-based system
Number of subjects: 6462
Study 27742394 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-egg powder
Number of subjects: 319
Study 27742394 — intervention group
Group type: COMPARATOR
Intervention: Placebo (rice powder)
Number of subjects: 319
Study 26170041 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and leucine-enriched whey protein nutritional supplement
Number of subjects: 380
Study 26170041 — intervention group
Group type: COMPARATOR
Intervention: Iso-caloric control product
Number of subjects: 380
Study 24021479 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance tests (OGTTs) and waist measurement
Number of subjects: 0
Study 21306829 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 159
Study 21306829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 19693675 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcon-60s
Number of subjects: 75
Study 19693675 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcon-30s
Number of subjects: 75
Study 19693675 — intervention group
Group type: COMPARATOR
Intervention: Routine
Number of subjects: 75
Study 17578485 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole 0.5 mg
Number of subjects: 16
Study 17578485 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Pramipexole 0.5 mg and Domperidone 40 mg
Number of subjects: 16
Study 17578485 — intervention group
Group type: EXPERIMENTAL
Intervention: Domperidone 40 mg
Number of subjects: 16
Study 17578485 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 14969424 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive perception of deviant signal (stimuli evoking mismatch negativity)
Number of subjects: 0
Study 14969424 — intervention group
Group type: COMPARATOR
Intervention: Passive perception of stimuli not evoking mismatch negativity
Number of subjects: 0
Study 11037740 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-isosorbide-mononitrate (5-ISMN) 30 mg administered orally three times daily for 4 weeks
Number of subjects: 9
Study 11037740 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 9
Study 9265038 — intervention group
Group type: EXPERIMENTAL
Intervention: TX 1341 (3 chewable lactate and citrate of magnesium tablets, each containing 120 mg of magnesium-element)
Number of subjects: 179
Study 9265038 — intervention group
Group type: COMPARATOR
Intervention: Reference magnesium (MAG2, 3 drinkable ampoules of pidolate of magnesium, each containing 122 mg of magnesium-element)
Number of subjects: 179
Study 9265038 — intervention group
Group type: EXPERIMENTAL
Intervention: TX 1341
Number of subjects: 179
Study 9265038 — intervention group
Group type: COMPARATOR
Intervention: Reference magnesium
Number of subjects: 179
Study 9265038 — intervention group
Group type: EXPERIMENTAL
Intervention: Both TX 1341 and Reference magnesium
Number of subjects: 179
Study 1473444 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% carbachol
Number of subjects: 60
Study 1473444 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 60
Study 4034460 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecatwin
Number of subjects: 780
Study 4034460 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoccult
Number of subjects: 780
Study 31852916 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence module
Number of subjects: 298
Study 31852916 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect module
Number of subjects: 298
Study 31852916 — intervention group
Group type: EXPERIMENTAL
Intervention: Perspective module
Number of subjects: 298
Study 29701167 — intervention group
Group type: EXPERIMENTAL
Intervention: Maze procedure (AF ablation device)
Number of subjects: 352
Study 29701167 — intervention group
Group type: COMPARATOR
Intervention: Control (routine cardiac surgery without maze procedure)
Number of subjects: 352
Study 27326985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine, fexofenadine, bilastine, desloratadine, or ebastine (daily oral dose for 8 weeks)
Number of subjects: 150
Study 27326985 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose of antihistamine after 4 weeks for non-responders
Number of subjects: 150
Study 27326985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antihistamine treatment)
Number of subjects: 150
Study 24736647 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 g of EPA+DHA daily oil capsule supplements (n=24)
Number of subjects: 45
Study 24736647 — intervention group
Group type: COMPARATOR
Intervention: Identical appearing soybean oil (n=21)
Number of subjects: 45
Study 22568611 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency TENS (100 Hz frequency, 75 µs pulse for 60 min)
Number of subjects: 40
Study 22568611 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 40
Study 20571241 — intervention group
Group type: EXPERIMENTAL
Intervention: Pringle maneuver
Number of subjects: 25
Study 20571241 — intervention group
Group type: COMPARATOR
Intervention: Control (no clamping)
Number of subjects: 25
Study 18665018 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-part brief counseling intervention
Number of subjects: 93
Study 18665018 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 93
Study 15817850 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-protein (LF-HP) diet (29 ± 1% fat, 34 ± 0.8% protein)
Number of subjects: 57
Study 15817850 — intervention group
Group type: COMPARATOR
Intervention: High-fat, standard-protein (HF-SP) diet (45 ± 0.6% fat, 18 ± 0.3% protein)
Number of subjects: 57
Study 15817850 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 57
Study 12613519 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline treatment with average dose of 174 mg/m2 (median 200 mg/m2) and mediastinum irradiation dose of 21 Gy (median 30 Gy)
Number of subjects: 88
Study 9750444 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g of tranexamic acid after induction of anesthesia and 3 g after CPB (group T)
Number of subjects: 28
Study 7625419 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg for 2 years
Number of subjects: 188
Study 7625419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 2778913 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional-hygienic intervention
Number of subjects: 201
Study 2778913 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study 354736 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional bowel preparation (CBP) using oral magnesium sulphate, enemas and rectal washouts
Number of subjects: 88
Study 354736 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole bowel irrigation (WBI) via a nasogastric tube
Number of subjects: 88
Study 354736 — intervention group
Group type: EXPERIMENTAL
Intervention: Elemental diet (ED)
Number of subjects: 88
Study 354736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral neomycin and metronidazole for 48 h before operation added to all three methods of bowel preparation
Number of subjects: 88
Study 354736 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bowel preparation)
Number of subjects: 88
Study 31805256 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose NL003
Number of subjects: 200
Study 31805256 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle-dose NL003
Number of subjects: 200
Study 31805256 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose NL003
Number of subjects: 200
Study 31805256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 29748353 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban regimen (HD-ER)
Number of subjects: 21105
Study 29748353 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 21105
Study 29748353 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban regimen
Number of subjects: 21105
Study 27297209 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel microbial lipase (NM-BL)
Number of subjects: 35
Study 27297209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 24738517 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ethics training
Number of subjects: 72
Study 24738517 — intervention group
Group type: COMPARATOR
Intervention: Passive ethics training (Control)
Number of subjects: 72
Study 22267467 — intervention group
Group type: EXPERIMENTAL
Intervention: RBV dose ≥3.0 g/kg
Number of subjects: 951
Study 22267467 — intervention group
Group type: EXPERIMENTAL
Intervention: RBV dose <3.0 g/kg
Number of subjects: 951
Study 22267467 — intervention group
Group type: EXPERIMENTAL
Intervention: RBV dose >3.0 g/kg
Number of subjects: 951
Study 22267467 — intervention group
Group type: EXPERIMENTAL
Intervention: Undetectable HCV RNA at week 4
Number of subjects: 951
Study 20007431 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 31
Study 17622279 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive video game exercise (combined with stationary cycling)
Number of subjects: 14
Study 17622279 — intervention group
Group type: COMPARATOR
Intervention: Traditional aerobic training (stationary cycling alone)
Number of subjects: 14
Study 15908667 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus fluorouracil (CF)
Number of subjects: 218
Study 15908667 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin plus paclitaxel (CP)
Number of subjects: 218
Study 12392039 — intervention group
Group type: EXPERIMENTAL
Intervention: BiDil (a fixed combination of hydralazine and isosorbide dinitrate)
Number of subjects: 600
Study 12392039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 9836106 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal elastase-1 assay in coeliac patients
Number of subjects: 30
Study 9836106 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretin‐caerulein test in coeliac patients
Number of subjects: 30
Study 8008785 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenic training (relaxation)
Number of subjects: 16
Study 8008785 — intervention group
Group type: COMPARATOR
Intervention: Quiet rest (control)
Number of subjects: 16
Study 2480639 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 11
Study 19382124 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microl lavender capsules
Number of subjects: 97
Study 19382124 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 97
Study 484753 — intervention group
Group type: EXPERIMENTAL
Intervention: High-priority men receiving more invitations to be screened
Number of subjects: 18872
Study 484753 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics and risk factor variables (blood pressure, blood cholesterol, cigarette smoking levels)
Number of subjects: 18872
Study 484753 — intervention group
Group type: EXPERIMENTAL
Intervention: Whether or not a man received a medical care service within the preceding two years
Number of subjects: 18872
Study 31028746 — intervention group
Group type: EXPERIMENTAL
Intervention: STRONGkids tool
Number of subjects: 271
Study 31028746 — intervention group
Group type: COMPARATOR
Intervention: Anthropometric measurements
Number of subjects: 271
Study 30979559 — intervention group
Group type: COMPARATOR
Intervention: Group A (myopic non-glaucomatous individuals)
Number of subjects: 62
Study 30979559 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (myopic glaucoma patients)
Number of subjects: 62
Study 28279391 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyme honey
Number of subjects: 72
Study 28279391 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 72
Study 26352854 — intervention group
Group type: EXPERIMENTAL
Intervention: m-health+CP (automated feedback to CarePartners)
Number of subjects: 72
Study 26352854 — intervention group
Group type: COMPARATOR
Intervention: standard m-health (IVR calls without CarePartner feedback)
Number of subjects: 72
Study 26352854 — intervention group
Group type: EXPERIMENTAL
Intervention: m-health+CP
Number of subjects: 72
Study 25170012 — intervention group
Group type: EXPERIMENTAL
Intervention: Crizotinib 250 mg orally twice daily
Number of subjects: 347
Study 25170012 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (docetaxel or pemetrexed)
Number of subjects: 347
Study 22669546 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly crosslinked polyethylene (XLPE)
Number of subjects: 60
Study 22669546 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene (PE)
Number of subjects: 60
Study 22669546 — intervention group
Group type: EXPERIMENTAL
Intervention: XLPE
Number of subjects: 60
Study 22669546 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 19467368 — intervention group
Group type: EXPERIMENTAL
Intervention: 32 U BoNTA
Number of subjects: 60
Study 19467368 — intervention group
Group type: EXPERIMENTAL
Intervention: 64 U BoNTA
Number of subjects: 60
Study 19467368 — intervention group
Group type: EXPERIMENTAL
Intervention: 96 U BoNTA
Number of subjects: 60
Study 17498014 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual information (8-minute video)
Number of subjects: 111
Study 17498014 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative preparation (Control)
Number of subjects: 111
Study 15005434 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo axial
Number of subjects: 14
Study 15005434 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo gingival
Number of subjects: 14
Study 15005434 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro axial
Number of subjects: 14
Study 15005434 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro gingival
Number of subjects: 14
Study 11779724 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (1,600 or 3,200 microg/d) for 8 weeks
Number of subjects: 35
Study 11779724 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (1,600 microg/d) after initial treatment
Number of subjects: 35
Study 11779724 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide treatment
Number of subjects: 35
Study 9737754 — intervention group
Group type: EXPERIMENTAL
Intervention: Water temperature at 41.5 degrees C
Number of subjects: 6
Study 9737754 — intervention group
Group type: COMPARATOR
Intervention: Water temperature at 40.0 degrees C
Number of subjects: 6
Study 8126354 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory balance training
Number of subjects: 24
Study 2782749 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol 200 micrograms
Number of subjects: 8
Study 2782749 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 1,500 micrograms
Number of subjects: 8
Study 2782749 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline 500 micrograms
Number of subjects: 8
Study 1085495 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass surgery
Number of subjects: 58
Study 31146543 — intervention group
Group type: EXPERIMENTAL
Intervention: Art intervention
Number of subjects: 267
Study 31146543 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of art and Qigong
Number of subjects: 267
Study 31146543 — intervention group
Group type: COMPARATOR
Intervention: Qigong intervention
Number of subjects: 267
Study 31146543 — intervention group
Group type: COMPARATOR
Intervention: Integrated intervention (art and Qigong)
Number of subjects: 267
Study 26760574 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling on the most hyperalgesic active and latent MTrP
Number of subjects: 66
Study 26760574 — intervention group
Group type: COMPARATOR
Intervention: Dry needling only on the most hyperalgesic active MTrP
Number of subjects: 66
Study 27825008 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor milk
Number of subjects: 363
Study 27825008 — intervention group
Group type: COMPARATOR
Intervention: Preterm formula
Number of subjects: 363
Study 25470133 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocuff-assisted colonoscopy (EC)
Number of subjects: 500
Study 25470133 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (SC)
Number of subjects: 500
Study 22589297 — intervention group
Group type: EXPERIMENTAL
Intervention: Interhospital transfer for primary percutaneous coronary intervention
Number of subjects: 2075
Study 22589297 — intervention group
Group type: EXPERIMENTAL
Intervention: D1D2 time ≤150 minutes
Number of subjects: 2075
Study 22589297 — intervention group
Group type: EXPERIMENTAL
Intervention: D1D2 time >150 minutes
Number of subjects: 2075
Study 21055142 — intervention group
Group type: EXPERIMENTAL
Intervention: felodipine 5 mg q.d + irbesartan 150 mg q.d (F + I group, n = 49)
Number of subjects: 99
Study 21055142 — intervention group
Group type: COMPARATOR
Intervention: felodipine 5 mg q.d + metoprolol 47.5 mg q.d (F + M group, n = 50)
Number of subjects: 99
Study 18212287 — intervention group
Group type: EXPERIMENTAL
Intervention: Embolic protection devices (EPDs)
Number of subjects: 3958
Study 18212287 — intervention group
Group type: COMPARATOR
Intervention: No embolic protection devices (EPDs)
Number of subjects: 3958
Study 15749489 — intervention group
Group type: COMPARATOR
Intervention: IVF
Number of subjects: 38
Study 15749489 — intervention group
Group type: EXPERIMENTAL
Intervention: ICSI
Number of subjects: 38
Study 12886670 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group taking placebos (EGP)
Number of subjects: 59
Study 12886670 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group taking vitamin E (EGE)
Number of subjects: 59
Study 12886670 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary group taking vitamin E (SGE)
Number of subjects: 59
Study 12886670 — intervention group
Group type: COMPARATOR
Intervention: Sedentary group taking placebos (SGP)
Number of subjects: 59
Study 11030506 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care
Number of subjects: 111
Study 11030506 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Number of subjects: 111
Study 11030506 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergonomics
Number of subjects: 111
Study 11030506 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation and ergonomics
Number of subjects: 111
Study 11030506 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 111
Study 8971321 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiva polyurethane cannula
Number of subjects: 1008
Study 8971321 — intervention group
Group type: COMPARATOR
Intervention: Insyte polyurethane cannula
Number of subjects: 1008
Study 1336516 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM version 1.22
Number of subjects: 14
Study 1336516 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM version 1.24
Number of subjects: 14
Study 1336516 — intervention group
Group type: EXPERIMENTAL
Intervention: ROM version 1.28
Number of subjects: 14
Study 1336516 — intervention group
Group type: COMPARATOR
Intervention: ROM version 1.22 and 1.24
Number of subjects: 14
Study 3901207 — intervention group
Group type: EXPERIMENTAL
Intervention: imipenem/cilastatin
Number of subjects: 31
Study 3901207 — intervention group
Group type: COMPARATOR
Intervention: cefotaxime
Number of subjects: 31
Study 31355286 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccination (4 doses)
Number of subjects: 768
Study 31355286 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth dose of Hepatitis B vaccine
Number of subjects: 768
Study 31355286 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors influencing vaccination
Number of subjects: 768
Study 29537447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxymetazoline cream 1.0%
Number of subjects: 445
Study 29537447 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 445
Study 26747220 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin glue (cyanoacrylate) applied to the skin insertion site with standard securement
Number of subjects: 360
Study 26747220 — intervention group
Group type: COMPARATOR
Intervention: Standard securement (control group)
Number of subjects: 360
Study 24431911 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (300 mg/day)
Number of subjects: 121
Study 24431911 — intervention group
Group type: COMPARATOR
Intervention: Voglibose (0.9 mg/day)
Number of subjects: 121
Study 22951790 — intervention group
Group type: EXPERIMENTAL
Intervention: 380 mg XR‐NTX
Number of subjects: 250
Study 22951790 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study 20307032 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone injection
Number of subjects: 63
Study 20307032 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 63
Study 20307032 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radial optic neurotomy/intraocular triamcinolone injection
Number of subjects: 63
Study 18559703 — intervention group
Group type: EXPERIMENTAL
Intervention: HGF plasmid (high dose: 4.0 mg at days 0, 14, and 28)
Number of subjects: 104
Study 18559703 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study 18559703 — intervention group
Group type: EXPERIMENTAL
Intervention: HGF plasmid (low dose: 0.4 mg at days 0, 14, and 28)
Number of subjects: 104
Study 18559703 — intervention group
Group type: EXPERIMENTAL
Intervention: HGF plasmid (middle dose: 4.0 mg at days 0 and 28)
Number of subjects: 104
Study 15753793 — intervention group
Group type: EXPERIMENTAL
Intervention: Tl SPECT
Number of subjects: 26
Study 15753793 — intervention group
Group type: EXPERIMENTAL
Intervention: LDDE
Number of subjects: 26
Study 11952265 — intervention group
Group type: EXPERIMENTAL
Intervention: Children (6-12 years)
Number of subjects: 78
Study 11952265 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 78
Study 10326954 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine
Number of subjects: 19
Study 10326954 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine
Number of subjects: 19
Study 10326954 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 19
Study 7847516 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen (50 micrograms of estradiol daily) with levonorgestrel-releasing intrauterine device
Number of subjects: 40